A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
Peking University Cancer Hospital & Institute
Peking University Cancer Hospital & Institute
Henan Cancer Hospital
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Sun Yat-sen University
Betta Pharmaceuticals Co., Ltd.
Sichuan Cancer Hospital and Research Institute
Anhui Medical University
China Medical University, China
ChineseAMS
ChineseAMS
Beijing Haidian Hospital
Hangzhou Cancer Hospital
First People's Hospital of Hangzhou
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Nanfang Hospital, Southern Medical University
People's Hospital of Guangxi Zhuang Autonomous Region
Zhejiang University
Zhejiang University
Betta Pharmaceuticals Co., Ltd.
Nanfang Hospital, Southern Medical University
Betta Pharmaceuticals Co., Ltd.
Shandong Cancer Hospital and Institute
Zhejiang Cancer Hospital